Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in elective CABG to assess T3 levels and early postoperative outcomes
IRCT20241027063514N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in coronary arteriosclerosis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Alterations in T3 level, Length of stay in the ICU and 3 more. Started Dec 2025; status: completed.
02
Drugs
acetylcysteine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20241027063514N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241027063514N1.